

HUA MEDICINE

(stock code: 2552)

BUSINESS UPDATE ON COMPLETION OF DAWN (HMM0302), DORZAGLIATIN'S PHASE III METFORMIN COMBINATION TRIAL ANNOUNCEMENT OF POTENTIAL INSIDE INFORMATION

(Company , Group) 13.0 E 5 1).

1 , 2020, 0302), (DAWN Trial). EE (0301), (SEED Trial), 2020, 53- (52- -) 1,200 -1 , . , - - , - , , 2 (T2D).

_ 24- 52- 2 (1,500 /)

_ (3 /) 52- 1%

_ 24-

1.02% 1 5.45 /

(2) ,

0.0001

_ 1 , 24- 52-

_ EE , - 2

2- 2-

(2 2 0.1022 2.3 2 -1.1 (

Appendix 1

Hua Medicine Successfully Completes Its Registration Phase III Trials. Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial

□1 , 2020, , ,

, (Company , 2552.),

✓ 53- □ , □ □ □ 1,200+ -1 , , □ □ , □ , ,

✓ □ , □ 24- □ 52- □ 2 □ , □ □ □ □ □ (1,500□ /)


✓ □ □ , , □ , , □ □ , □ □ □ □ , □ □ □ □ □ □ (, 3 □ /) □ , □ 52- □ □ □ □ , □ □ 1%

✓ 24- □ □ , □□ □ □ 1.02% , 1 □ □ , □ - □ , □ , □ □ 5.45 □ / □ , - , (2 -) □ , □ , □ □ - 0.0001

✓ , 1 □ , , □ , 24- □ 52- □ □ □ □ □ □ □ , □

✓ □ □ □ □ EE □ , □ , - 2 □ , □ □ , □ 2- □ , □ 2- □ □ □ □ , □ , , , □ □ - □ □ , □ □ □ □ □ □ □

2



SEED Trial study design

About Dorzagliatin

About Hua Medicine

About Hua Medicine Portfolio Advisory Board

[illegible] (PAB